Antengene
Help people with cancer
live longer and better.
About us

About Us

Management Team


John Z. Gong,M.D.,Ph.D.

John Z. Gong,M.D.,Ph.D.

Chairman and CEO

— US FDA Reviewer for 10 years, conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics
— VP of Drug Development and Regulatory Affairs of BeiGene
— With more than 30 years of global industry and academic experience, Dr. John Gong devoted into new drug R&D in different stakeholders from FDA, CRO to biotech companies. He gained rich experience on following field: leading global new drug development, manufacture and commercialization, the process of identifying, license-in and co-development drug candidates, strategic planning for global development, registration and commercialization, pre-clinical and clinical trial designs, GLP/GCP/GMP regulations, project risk management
—  Ph.D. degree in Toxicology from New York University in 1996 and medical degree from Beijing Medical College in 1984

—  Member of editorial board of Chinese Journal of New Drugs, Progress in Pharmaceutical Sciences and DIA advisory committee, International Innovative Drug Supervision Professional Committee member of the PhIRDA

  • Jing Zhang

    Jing Zhang / USCPA

    Chief Financial Officer

    Bachelor’s degree in medical nutrition from Yat-sen University of Medical Sciences; Master in Accountancy, University of South Carolina

    — Member of AICPA, worked for United Technologies and Anthem, 20+ years as global healthcare financial management executive in US MNC, health insurance company and big 4 audit firms

  • Fang Xia

    Fang Xia

    Secretary to the Board, Head of Public Relations

    — Master in Pharmacognosy,Peking University Health Science Center,MBA in Harvard Business School.

    — Worked as deputy director of product design center in Taiji Group in Beijing,

    — Since 2016 entry 3D Medicines,has been serverd as the head of regulatory affairs of the Group and the vice president (副總經理) of 3D Medicines

    —Member of the Hong Kong Investor Relations Association and a member of the fourth (2022 2024) Professional Committee on China Pharmaceutical Innovation and Research Development Association (PhIRDA)

     

  • Ming Zhu

    Ming Zhu

    Vice President, Head of Company Operations

    — Bachelor in Finance, Suzhou University

    — Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, over 15 years' operation management experience

  • Yue He

    Yue He

    Executive Director, Quality Management

    — Master in Clinical Medicine in Sichuan University, MBA in Hong Kong Asia Business College

    — Worked for BeiGene,  Ronggang Biotechnology Pharma and Baitai Biopharmaceutical, 13 years of experience in the pharmaceutical industry

  • Jian Zhou, Ph.D.

    Jian Zhou, Ph.D.

    Vice President, Small Molecule CMC

    — Master in Medicinal Chemistry, Peking University; Ph.D. in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland

    — Comprehensive experience in drug R&D, manufacturing, quality research and the construction of pharmaceutical plants

  • Qiang Feng, Ph.D.

    Qiang Feng, Ph.D.

    Executive Director, Biopharmaceutical CMC

    — Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D. in Cell Biology, Fourth Military Medical University

    — Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R&D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects

  • Jing Zhang

    Jing Zhang / USCPA

    Chief Financial Officer

    — Bachelor’s degree in medical nutrition from Yat-sen University of Medical Sciences; Master in Accountancy, University of South Carolina

    — Member of AICPA, worked for United Technologies and Anthem, 20+ years as global healthcare financial management executive in US MNC, health insurance company and big 4 audit firms

  • Fang Xia

    Fang Xia

    Secretary to the Board, Vice President

    — Master in Pharmacognosy,Peking University Health Science Center,MBA in Harvard Business School.

    — Worked as deputy director of product design center in Taiji Group in Beijing, responsible for product registration and regulatory communication

     

  • Ming Zhu

    Ming Zhu

    Vice President, Head of Company Operations

    — Bachelor in Finance, Suzhou University

    — Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, over 15 years' operation management experience

     

  • Yue He

    Yue He

    Senior Director of the Quality Management

    — Master in Clinical Medicine in Sichuan University, MBA in Hong Kong Asia Business College

    — Worked for BeiGene,  Ronggang Biotechnology Pharma and Baitai Biopharmaceutical, 13 years of experience in the pharmaceutical industry

  • Jian Zhou, Ph.D.

    Jian Zhou, Ph.D.

    Vice President, Small Molecule CMC

    — Master in Medicinal Chemistry, Peking University; Ph.D. in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland

    — Comprehensive experience in drug R&D, manufacturing, quality research and the construction of pharmaceutical plants

  • Qiang Feng, Ph.D.

    Qiang Feng, Ph.D.

    Executive Director, Biopharmaceutical CMC

    — Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D in Cell Biology, Fourth Military Medical University

    — Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R&D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects.